1,018 Shares in Eli Lilly and Company (NYSE:LLY) Purchased by Lattice Capital Management LLC

Lattice Capital Management LLC bought a new stake in Eli Lilly and Company (NYSE:LLY) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 1,018 shares of the company’s stock, valued at approximately $786,000. Eli Lilly and Company comprises 0.6% of Lattice Capital Management LLC’s investment portfolio, making the stock its 14th biggest position.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Dahring Cusmano LLC purchased a new position in Eli Lilly and Company in the fourth quarter worth approximately $270,000. Blackston Financial Advisory Group LLC lifted its stake in shares of Eli Lilly and Company by 16.4% in the 4th quarter. Blackston Financial Advisory Group LLC now owns 511 shares of the company’s stock valued at $395,000 after purchasing an additional 72 shares during the last quarter. Transcend Capital Advisors LLC increased its position in shares of Eli Lilly and Company by 4.8% during the 4th quarter. Transcend Capital Advisors LLC now owns 17,335 shares of the company’s stock worth $13,383,000 after purchasing an additional 797 shares during the last quarter. Cassaday & Co Wealth Management LLC raised its holdings in Eli Lilly and Company by 0.8% in the 4th quarter. Cassaday & Co Wealth Management LLC now owns 5,615 shares of the company’s stock valued at $4,335,000 after buying an additional 45 shares during the period. Finally, Arcadia Investment Management Corp MI lifted its position in Eli Lilly and Company by 79.4% in the fourth quarter. Arcadia Investment Management Corp MI now owns 4,300 shares of the company’s stock valued at $3,320,000 after buying an additional 1,903 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the subject of a number of recent analyst reports. Redburn Atlantic upgraded shares of Eli Lilly and Company to a “hold” rating in a research report on Monday, November 4th. Citigroup cut their target price on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. StockNews.com upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Barclays dropped their price objective on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research note on Thursday, October 31st. Finally, Wolfe Research began coverage on Eli Lilly and Company in a research note on Friday, November 15th. They set an “outperform” rating and a $1,000.00 target price on the stock. Three research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $1,007.94.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $874.12 on Friday. Eli Lilly and Company has a 12 month low of $711.40 and a 12 month high of $972.53. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The firm has a market capitalization of $829.82 billion, a PE ratio of 74.65, a price-to-earnings-growth ratio of 1.39 and a beta of 0.42. The business’s fifty day moving average price is $801.33 and its 200 day moving average price is $846.75.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 86.26% and a net margin of 23.51%. On average, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company announced that its Board of Directors has approved a stock buyback program on Monday, December 9th that authorizes the company to buyback $15.00 billion in outstanding shares. This buyback authorization authorizes the company to purchase up to 2% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be given a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.69%. The ex-dividend date is Friday, February 14th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s payout ratio is currently 51.24%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.